Concepedia

Corine Holub

CH

Statistics

Publications

5

Citations

81

H-Index

5

Active since

2016

Affiliations

Takeda (United States)(Current)

Takeda (Japan)

Corine Holub is an author at Takeda (United States) specializing in fragment-based ligand design, fragment-based pharmacophore design, and fragment-based lead design.

ORCID

Publications per year

2016–2022

5

Publications

5

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2

Christopher M. McBride, Zacharia S. Cheruvallath, Mallareddy Komandla et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 24 citations · Full text

, , +16

Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells

Shan Yu, Matthew Ericson, Andrea Fanjul et al. · ACS Chemical Biology · 2022 · 17 citations · Full text

, , +17

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1

Zacharia S. Cheruvallath, Mingnam Tang, Christopher M. McBride et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 16 citations · Full text

, , +16

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes

Huey-Jing Huang, Corine Holub, Paul Rolzin et al. · Journal of Biological Chemistry · 2019 · 14 citations · Full text

, , +17

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

Pamela Farrell, Christopher J. Zopf, Huey-Jing Huang et al. · Journal of Pharmacology and Experimental Therapeutics · 2019 · 10 citations · Full text

, , +16

1–5 of 5